What biomarker testing is recommended for metastatic Colorectal Cancer

Biomarker Testing for Metastatic Colorectal Cancer

When colorectal cancer has spread to distant sites (metastatic disease), biomarker testing becomes crucial for guiding treatment decisions. Here's what the current medical guidelines recommend:

Core Biomarkers That Should Be Tested

According to NCCN Guidelines for Colon Cancer, all patients with metastatic colorectal cancer (mCRC) should have their tumors tested for:

1. RAS Mutations (KRAS and NRAS)

• What it means: These genes control cell growth signals. Mutations in KRAS or NRAS (in exons 2, 3, or 4) make the cancer resistant to certain targeted therapies
• Why it matters: If your tumor has a KRAS or NRAS mutation, you cannot benefit from cetuximab or panitumumab (EGFR inhibitors), even though these drugs might otherwise be options
• Exception: There's a specific exception for KRAS G12C mutations, which can be treated with targeted drugs like sotorasib or adagrasib

2. BRAF Mutations

• What it means: A BRAF V600E mutation indicates a different type of growth signal problem in your cancer cells
• Why it matters: BRAF mutations make response to cetuximab or panitumumab highly unlikely unless combined with a BRAF inhibitor
• Testing method: Can be detected via immunohistochemistry (IHC) or DNA sequencing

3. Mismatch Repair (MMR) Status or Microsatellite Instability (MSI)

• What it means: These tests check if your cancer cells have defects in their DNA repair machinery
• Why it matters:
  • dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high) tumors may respond to immunotherapy drugs like pembrolizumab
  • This status helps identify Lynch syndrome risk
• Testing methods: Immunohistochemistry (IHC) for MMR proteins OR DNA analysis for MSI

4. HER2 Amplification

• What it means: Extra copies of the HER2 gene, which drives cancer cell growth
• Why it matters: HER2-amplified tumors (in patients with wild-type RAS and BRAF) can be treated with anti-HER2 therapies like trastuzumab combined with other targeted drugs
• Testing methods: IHC (immunohistochemistry), FISH (fluorescence in situ hybridization), or NGS (next-generation sequencing)

Additional Testing to Consider

5. Next-Generation Sequencing (NGS) Panels

The NCCN Guidelines recommend that testing be performed as part of broad molecular profiling (NGS panel preferred) because it can identify rare but actionable mutations and fusions, including:

• NTRK fusions (extremely rare in CRC ~0.35%, but treatable with NTRK inhibitors)
• RET fusions (also rare, but actionable)
• POLE/POLD1 mutations (associated with ultra-hypermutated tumors that may respond to immunotherapy)

6. PIK3CA Testing

• The NCCN Guidelines suggest considering PIK3CA testing for stage II-III disease, and this may extend to metastatic disease for treatment planning

How Testing Is Performed

According to NCCN Guidelines, biomarker testing can be done on:

• Tissue samples (preferred): From your primary tumor or metastatic site
• Blood-based assays: Circulating tumor DNA (ctDNA) from a blood draw is an acceptable alternative
• CLIA-certified laboratories: Testing must be performed in laboratories certified under Clinical Laboratory Improvement Amendments (CLIA-88)

Important Clinical Considerations

Repeat Testing After Treatment:

• Standard cytotoxic chemotherapy rarely causes significant molecular changes, so repeat testing after chemotherapy is not recommended
• However, repeat testing may be considered after targeted therapies to detect acquired mutations that could guide future treatment decisions

Timing:

• Biomarker testing should be done early in your metastatic disease workup to inform initial treatment planning

Questions to Ask Your Oncology Team

1. Has my tumor been tested for all recommended biomarkers (KRAS, NRAS, BRAF, MMR/MSI, HER2)?
2. Was an NGS panel used, or were individual genes tested separately? (NGS panels can catch rare actionable mutations)
3. Based on my specific biomarker results, what treatment options are most appropriate for me?
4. Will my tumor be retested if my cancer progresses or if I receive targeted therapy?
5. Are there any clinical trials available for my specific biomarker profile?

---

Key Sources

According to the NCCN Guidelines for Colon Cancer (Version 5.2025), comprehensive biomarker testing is now standard of care for metastatic disease. The American Society of Clinical Oncology (ASCO) has also released guidance consistent with these recommendations for extended RAS testing in mCRC patients.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.